U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
GAITHERSBURG, Md., April 27, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that Tina S. Nova, Ph.D. has been appointed to its Board of Directors.
Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses. She currently serves as president and chief executive officer of Molecular Stethoscope, Inc., a newly formed molecular diagnostics company. Most recently, she was senior vice president and general manager of Illumina's oncology business unit. From 2000 to 2014, Dr. Nova was a co-founder and director, president and chief executive officer of Genoptix Medical Laboratory, which was purchased by Novartis Pharmaceuticals Corporation for nearly $0.5 billion in 2011. She has also held senior positions with Nanogen, Inc., Ligand Pharmaceuticals, Inc. and Hybritech, Inc. Dr. Nova currently serves on the board of directors for Arena Pharmaceuticals and Veracyte and is vice chairman of the board of directors for the newly formed Rady Pediatric Genomics and Systems Medicine Institute, which is part of Rady Children's Hospital-San Diego. Dr. Nova holds a B.S. degree in Biological Sciences from the University of California, Irvine where she graduated with honors and a Ph.D. in Biochemistry from the University of California, Riverside.
“We are pleased to have Dr. Nova, a seasoned industry expert with a portfolio of high caliber successes, join the OpGen Board,” said Evan Jones, Chairman and CEO of OpGen. “Dr. Nova’s insights and experience from having built and advised successful molecular diagnostics companies will be invaluable as we continue to advance the development of our Acuitas Rapid Test and Acuitas Lighthouse Knowledgebase to combat the rise of multidrug-resistant organisms in our hospitals and health systems.”
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Contact: OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-591-3443 [email protected]
